🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
LLY
NYSE
🇺🇸 US
Eli Lilly and Company
Pharmaceuticals
23Score
DipBuster Score™
$1,417.54
+$43.84 (+3.19%)
Live price · Source: Yahoo
52-Week Position
$850.51
95% of range
$1,449.68
Beta
0.453
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.453
52W High$1,449.68
52W Low$850.51
DipBuster Brief
Key signals at a glance
Zone: Sell / Avoid
Bearish
Near 52-Week High — Asymmetric Risk
At 95% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position95% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.453
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Eli Lilly and Company (LLY), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-10-19 | Luciano Juan R | BUY | 13 |
| 2026-10-19 | Fyrwald J Erik | BUY | 8 |
| 2026-10-19 | Alvarez Ralph | BUY | 10 |
| 2026-10-19 | Sulzberger Gabrielle | BUY | 4 |
| 2026-09-21 | Luciano Juan R | BUY | 14 |
| 2026-09-21 | Fyrwald J Erik | BUY | 9 |
| 2026-09-21 | Alvarez Ralph | BUY | 11 |
| 2026-09-21 | Sulzberger Gabrielle | BUY | 4 |
| 2026-09-09 | Seymour Melissa | SELL | 12 |
| 2026-09-02 | Dozier Eric | SELL | 216 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.453
Dividend/yrNone
52W High$1,449.68
52W Low$850.51
52-Week Range
$850.51Now$1,449.68
95% through annual range
From 52W High−2.2%
From 52W Low+66.7%
📖 Plain English Summary
Eli Lilly and Company is at 95% of its 52-week range. Beta 0.453 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for LLY
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — LLY
Heuristic · balance sheet, insider filings, price data, academic research
Eli Lilly and Company — DipBuster Score 23/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Eli Lilly and Company free
Add LLY to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
2/25
Momentum & Volume
16/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 23/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite o…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
David A. Ricks
Staff
50,000 employees
Website